


**IN THE CLAIMS:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Original) A compound of formula I



in which



X is H, -OH, -OA, phenoxy, Ar, -O-CO-A, SO<sub>3</sub>H, SO<sub>3</sub>A, -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A, SO<sub>2</sub>A, Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or SO<sub>2</sub>NH<sub>2</sub>,  
or

two radicals X together are methylenedioxy or ethylenedioxy,

R<sup>1</sup> is H, A, -OH, -OA or Hal, or two radicals R<sup>1</sup> together are methylenedioxy or ethylenedioxy,

Y is CH or N,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

m is 1, 2, 3, 4 or 5, or


a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

2. **(Original)** A compound according to Claim 1,  
in which

X is H, -OH or -OA, or

two radicals X together are methylenedioxy or ethylenedioxy, or a salt or a solvate or  
a mixture of stereoisomers or isolated stereoisomer thereof.



3. **(Original)** A compound according to Claim 1,  
in which

R is A or , and

X is H, -OH or -OA, or

two radicals X together are methylenedioxy or ethylenedioxy, or a salt or a solvate or  
a mixture of stereoisomers or isolated stereoisomer thereof.

4. **(Original)** A compound according to Claim 1,  
in which

R is A,  or ,

X is H, -OH or -OA,

Y is N,

R<sup>1</sup> is A,


A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1, 2, 3 or 4, and

m is 1, 2, 3 or 4, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

5. **(Original)** A compound according to Claim 1,  
in which



X is H, -OH or -OA,

R<sup>1</sup> is A,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1, 2, 3 or 4, and

m is 1, 2, 3 or 4, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

6. **(Original)** A compound according to Claim 1 selected from 6-hydroxy-2-[3-(4-tert-

butylphenyl)-1,2,4-oxadiazol-5-yl]chromone, 7-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone, or 6-hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone, a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

7. **(Original)** A pharmaceutical composition comprising a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.

8. **(Cancelled)**

9. **(Original)** A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

10. **(Original)** A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.

11. **(Original)** A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.

12. **(Cancelled)**

13. **(Cancelled)**

14. **(Original)** A method of treating retinal vascularisation in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

15. **(Original)** A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

16. **(Original)** A method of treating an age-related macular degeneration in a mammal

comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

17. **(Original)** A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

18. **(Original)** A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.

19. **(Original)** A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

20. **(Original)** A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

21. **(Original)** A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.

22. **(Original)** A pharmaceutical composition according to claim 7, further comprising an additional pharmaceutically active compound.

23. **(Original)** A kit comprising separate packs of

(a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,

and

(b) an additional pharmaceutically active compound or composition.

24. **(Original)** A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a

cytotoxic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.

25.     **(Original)**     A method according to claim 24, further comprising performing radiotherapy on said mammal.

26.     **(Original)**     A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

27.     **(Original)**     A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.

28.     **(Original)**     A food supplement comprising a compound of claim 1.

29.     **(Original)**     A cosmetic composition comprising a compound of claim 1.

30.     **(Original)**     A method of protecting the proteins of the skin from stress comprising applying a cosmetic composition of claim 29 to the skin.


31.     **(Original)**     A topically applicable cosmetic composition comprising a compound of claim 1.

32.     **(Original)**     A cosmetic composition according to claim 29, containing 0.0001 to 50% by weight of a compound of claim 1.

33.     **(Cancelled)**


34.     **(Original)**     A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof, comprising

a) reacting a compound of formula II




in which

$X$  and  $n$  are as defined in Claim 1, with a compound of formula III



in which


$A$  is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, to give a compound of formula IV



in which

$X$  and  $n$  are as defined in Claim 1, and  $A$  is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,


b) then hydrolysing the compound of formula IV to a compound of formula V



in which


$X$  and  $n$  are as defined in Claim 1,

c) then converting the compound of formula V to a compound of formula VI




in which

$X$  and  $n$  are as defined in Claim 1, and then either reacting the compound of formula VI with a compound of formula VII



in which

$R$  is as defined in Claim 1, to give a compound of formula I, or reacting the compound of formula V with a compound of formula VII





in which

R is as defined in Claim 1, in a two-step, one-pot reaction to give a compound of formula I, and/or

- d) a compound of formula I is converted into a salt or into a solvate and/or a stereoisomer of a compound of formula I is isolated.